ZA200801959B - Immunotherapeutic treatment for inducing the regression of atherosclerotic plaques - Google Patents

Immunotherapeutic treatment for inducing the regression of atherosclerotic plaques

Info

Publication number
ZA200801959B
ZA200801959B ZA200801959A ZA200801959A ZA200801959B ZA 200801959 B ZA200801959 B ZA 200801959B ZA 200801959 A ZA200801959 A ZA 200801959A ZA 200801959 A ZA200801959 A ZA 200801959A ZA 200801959 B ZA200801959 B ZA 200801959B
Authority
ZA
South Africa
Prior art keywords
regression
inducing
atherosclerotic plaques
immunotherapeutic treatment
immunotherapeutic
Prior art date
Application number
ZA200801959A
Other languages
English (en)
Inventor
Carlsson Roland
Nilsson Jan
Original Assignee
Biolnvent Internat Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolnvent Internat Ab filed Critical Biolnvent Internat Ab
Publication of ZA200801959B publication Critical patent/ZA200801959B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0012—Lipids; Lipoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200801959A 2005-09-02 2008-02-29 Immunotherapeutic treatment for inducing the regression of atherosclerotic plaques ZA200801959B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0517878.5A GB0517878D0 (en) 2005-09-02 2005-09-02 Immunotherapeutic treatment

Publications (1)

Publication Number Publication Date
ZA200801959B true ZA200801959B (en) 2009-08-26

Family

ID=35220745

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200801959A ZA200801959B (en) 2005-09-02 2008-02-29 Immunotherapeutic treatment for inducing the regression of atherosclerotic plaques

Country Status (16)

Country Link
US (1) US20090208503A1 (no)
EP (2) EP2319868A1 (no)
JP (1) JP2009506995A (no)
KR (2) KR20120101074A (no)
CN (1) CN101316863A (no)
AU (1) AU2006286729A1 (no)
BR (1) BRPI0615313A2 (no)
CA (1) CA2621017A1 (no)
GB (1) GB0517878D0 (no)
IL (1) IL189847A (no)
NO (1) NO20080951L (no)
NZ (1) NZ566237A (no)
RU (1) RU2454428C2 (no)
UA (1) UA96275C2 (no)
WO (1) WO2007025781A2 (no)
ZA (1) ZA200801959B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104194A1 (en) * 2007-02-28 2008-09-04 Bioinvent International Ab Oxidized ldl and antibodies thereto for the treatment of atheroscleroti c plaques
CN101951885A (zh) * 2007-12-28 2011-01-19 生物发明国际公司 制剂
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
EP2637689A2 (en) * 2010-11-12 2013-09-18 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of hypertension
EP2592423A1 (en) * 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
WO2019210207A2 (en) * 2018-04-27 2019-10-31 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor t regulatory cells for the treatment of atherosclerosis
WO2019215300A1 (en) 2018-05-09 2019-11-14 Medirista Biotechnologies Ab Antibodies for use in combination therapy
WO2019232081A1 (en) * 2018-05-29 2019-12-05 Abcentra, Llc Compositions and methods for treatment of rheumatoid arthritis and accelerated atherosclerosis
WO2020010024A1 (en) * 2018-07-02 2020-01-09 Abcentra, Llc Compositions and methods for reduction of lipoprotein a formation and treatment of aortic valve sclerosis and aortic stenosis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US20030157567A1 (en) * 1999-09-20 2003-08-21 Joe Lunec Oxidised fragments of apolipoprotein B and their use
US6716410B1 (en) 1999-10-26 2004-04-06 The Regents Of The University Of California Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
MXPA02007449A (es) * 2000-02-03 2003-04-14 Millennium Pharm Inc Anticuerpos anti-ccr2 humanizados y metodos para el uso de los mismos.
DE10059930A1 (de) * 2000-11-23 2002-05-29 Fischer Peter Mittel humanen Ursprungs zur Vakzination gegen GD2-pos. Tumore
US20030105003A1 (en) * 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
SE0103754L (sv) 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
DE10123074A1 (de) 2001-05-10 2002-11-14 Monforts Textilmaschinen Gmbh Vorrichtung zur Wärmebehandlung einer Warenbahn
AU2003267905B2 (en) 2002-10-04 2009-02-05 Biolnvent International Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
SE0302312D0 (sv) * 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis

Also Published As

Publication number Publication date
NO20080951L (no) 2008-06-02
KR20080053483A (ko) 2008-06-13
UA96275C2 (ru) 2011-10-25
IL189847A0 (en) 2008-11-03
JP2009506995A (ja) 2009-02-19
KR20120101074A (ko) 2012-09-12
EP2319868A1 (en) 2011-05-11
BRPI0615313A2 (pt) 2012-12-04
GB0517878D0 (en) 2005-10-12
WO2007025781A3 (en) 2007-05-03
RU2008112664A (ru) 2009-10-10
RU2454428C2 (ru) 2012-06-27
AU2006286729A1 (en) 2007-03-08
US20090208503A1 (en) 2009-08-20
CN101316863A (zh) 2008-12-03
NZ566237A (en) 2011-07-29
EP1928913A2 (en) 2008-06-11
WO2007025781A2 (en) 2007-03-08
CA2621017A1 (en) 2007-03-08
EP1928913B1 (en) 2013-06-26
IL189847A (en) 2012-02-29

Similar Documents

Publication Publication Date Title
HUS1900005I1 (hu) Javított nanotestek (TM) aggregáció közvetítette rendellenességek kezelésére
ZA200801959B (en) Immunotherapeutic treatment for inducing the regression of atherosclerotic plaques
IL185016A0 (en) Compounds for the treatment of proliferative disorders
HK1127489A1 (en) Pyridiazinone derivatives for the treatment of tumours
PL1942857T3 (pl) Aparat do masażu
GB2430881B (en) Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity
IL179508A0 (en) 2-substituted-4- heteroaryl-pyrimidines useful for the treatment of proliferative disorders
EP1853539A4 (en) HONOKIOL DERIVATIVES TO TREAT PROLIFERATIVE DISEASES
EP1893570A4 (en) IMPROVED PROCESS FOR THE PREPARATION OF EZETIMIBE
IL188204A0 (en) Combination therapy for the treatment of immunoinflammatory disorders
IL188430A0 (en) Treatment of tumors
IL178578A (en) Desulfeptohyrodine or a variant of Desulfatohyrodine to cause tumor regression
PL1907374T3 (pl) Pochodne benzylopiperazyny użyteczne do leczenia zaburzeń układu pokarmowego
ZA200806455B (en) Use of 2-imidazoles for the treatment of CNS disorders
ZA200704610B (en) Treatment apparatus
ZA200805159B (en) Imidazole derivatives for the treatment of gastrointestinal disorders
IL184330A0 (en) Treatment apparatus
GB0517387D0 (en) Combinations for the treatment of cancer
GB0515035D0 (en) Treatment of atherosclerotic conditions
IL192877A0 (en) Use of 2-imidazoles for the treatment of cns disorders
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
ZA200805522B (en) Dioxoiane dérivates for the treatment of cancer
IL178907A0 (en) Use of sulglicotide for the treatment of mucositis
GB0517386D0 (en) Combinations for the treatment of cancer
TJ20050863A (en) The way of narcotism treatment